Austrian Phagomed wants to close a Series A financing in 2020. The start-up is working on phage-based treatments as a new alternative to antibiotics.
London-based Syncona Ltd announces the appointment of Danny Bar-Zohar as Syncona Partner, starting mid of April.
Belgian Bone Therapeutics SA has secured €11m to foster development of its late stage pipeline candidates.
Cevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
German vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.
German researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model.
BIO-Europe Spring: Leading life sciences partnering event pivots to deliver dealmaking
opportunities in a new format during very unusual times. With just 16 days to plan, EBD Group transformed BIO-Europe Spring from a physical event held in Paris to a fully digital solution where 1,700 delegates around the world participated in virtual partnering meetings and panels.
It’s a discovery that revolutionises our fundamental understanding of cells. Tiny droplets called condensates that form through weak interactions between proteins and RNA are at the heart of many key biological processes. Dewpoint Therapeutics – the first start-up to harness the basic research for a new therapeutic platform technology – is now opening a facility in the German capital Berlin.
The acoustic dispensing technology of the Echo-Series Liquid Handlers has revolutionised the transfer of liquids.